Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

ARS Pharmaceuticals (SPRY) EPS (Basic) (2021 - 2025)

ARS Pharmaceuticals' EPS (Basic) history spans 5 years, with the latest figure at -$0.42 for Q4 2025.

  • For Q4 2025, EPS (Basic) fell 182.35% year-over-year to -$0.42; the TTM value through Dec 2025 reached -$1.74, down 2275.0%, while the annual FY2025 figure was -$1.74, 2275.0% down from the prior year.
  • EPS (Basic) for Q4 2025 was -$0.42 at ARS Pharmaceuticals, up from -$0.51 in the prior quarter.
  • Across five years, EPS (Basic) topped out at $1.19 in Q4 2021 and bottomed at -$0.7 in Q2 2021.
  • The 5-year median for EPS (Basic) is -$0.27 (2025), against an average of -$0.16.
  • The largest annual shift saw EPS (Basic) surged 71.63% in 2023 before it plummeted 253.85% in 2025.
  • A 5-year view of EPS (Basic) shows it stood at $1.19 in 2021, then dropped by 26.05% to $0.88 in 2022, then crashed by 45.25% to $0.48 in 2023, then increased by 5.85% to $0.51 in 2024, then plummeted by 182.35% to -$0.42 in 2025.
  • Per Business Quant, the three most recent readings for SPRY's EPS (Basic) are -$0.42 (Q4 2025), -$0.51 (Q3 2025), and -$0.46 (Q2 2025).